K
Kimberly-Clark Corporation
KMB · Consumer Defensive
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
Durable Cash Machine Priced as Though the Moat Is Already Gone
The market has repriced KMB as a secularly impaired business, but the earnings and FCF yields at current prices embed an assumption of terminal decay that the actual cash generation record doesn't support — the 2025 revenue collapse is portfolio surgery, not demand destruction, and that distinction carries enormous weight for where fair value actually sits.
Flowly Score
Apr 16 Close
+99%$97.97
Fair Value
$195.00
60
Averageat $97.97
Business Strength6/10
Genuine brand equity and mid-twenties ROIC prove a real moat exists, but it's holding at altitude rather than climbing — tissue commoditizes structurally, personal care concentration creates hidden demographic risk, and the moat materials are habit and shelf placement rather than anything harder to breach.
Financial Resilience7/10
Operating cash clears net income every single year without exception, Piotroski and Altman readings both confirm underlying financial health, and the leverage is a deliberate management choice rather than a sign of distress — the 2025 CapEx spike is the one yellow flag that warrants watching.
Growth & Trajectory4/10
Organic volume has been stubbornly elusive for years with pricing and buybacks doing most of the earnings work; the Costco distribution loss adds a concrete near-term headwind, and adult incontinence and emerging market tailwinds are real but not yet large enough to bend the overall growth curve.
Valuation7/10at $102.85
The P/E has compressed from the mid-twenties to the mid-teens while the cash engine proved durable through a full commodity cycle — even the pessimistic DCF scenario implies meaningful upside, suggesting the market is pricing in more structural decay than the financial evidence currently supports.
Risk6/10
Non-cyclical necessity products provide genuine resilience and the financial health metrics rule out near-term distress, but private label sophistication is a slow structural erosion rather than a manageable cyclical risk, and a well-resourced competitor retains the firepower to contest every major geography that matters.
The investment case rests on a gap between perception and reality: the market has priced this as a structurally declining business while the financials show a high-ROIC cash machine with brand positions in categories driven by bodily necessity. Operating cash exceeds reported earnings in every recent year, the balance sheet is healthy by two independent measures, and a P/E that compressed from the mid-twenties to the mid-teens reflects accumulated anxiety about private label and birth rates rather than documented earnings destruction. The current yields compensate investors for risks that haven't fully materialized. The trajectory is slow and honest — this grows roughly at population plus inflation, with real acceleration pockets in adult incontinence and Southeast Asian diaper adoption that the market consistently underweights. The Costco distribution loss is a real but bounded headwind that will eventually lap. The more interesting variable is whether the ongoing transformation unlocks a sharper-focused business or simply produces another chapter in a very long restructuring novel. The single most concrete risk is private label acceleration in tissue, not diapers. Huggies benefits from the emotional purchase dynamic — parents don't experiment with warehouse-brand newborn diapers — but Cottonelle competes in a category where 'soft enough' is genuinely good enough, and every incremental improvement in private label quality narrows the premium justification. That slow leak doesn't sink the ship in five years, but it quietly erodes the pricing power that makes tissue margins look as durable as they do today.